Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Inclusion Criteria

• Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
• Female subject is either post-menopausal or surgically sterilized or willing to use acceptable method of birth control for duration of study.
• Male subject agrees to use acceptable method for contraception for duration of study.
• Histologically-confirmed indolent or mantle cell lymphoma, utilizing the World Health Organization (WHO) classification. The biopsy must fulfill one of the following criteria:
• Follicular lymphoma, grades 1-3
• Marginal zone lymphoma
• Small lymphocytic lymphoma (circulating lymphocyte count must be 6 months, then patient is allowed to enroll on the study.
• Patient has concomitant active malignancy requiring therapy
• Patient is known to be HIV positive (test result not required for enrollment).
• History of solid organ transplantation, or post transplant lymphoproliferative disorder
• Patient has history of allogeneic stem cell transplantation.
• Patient has history of autologous stem cell transplantation or radioimmunotherapy within the previous 4 months.
• Patient has received any other investigational drugs within 14 days prior to enrollment
• History of, or clinically apparent CNS lymphoma
• Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis results that, in the judgment of the investigator, would impede adequate evaluation of adverse events and/or response to treatment, or that requires aggressive intervention